Researchers are excited about this new drug, a groundbreaking dual agonist showing promising results in clinical trials for size management. It works by impacting several systems: GLP-1 and GIP, that , when activated , support influence appetite and improve calorie burn. Early findings indicate considerable size management and possible benefits for